Search results
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Crohn's Disease
Zacks via Yahoo Finance· 2 years agoThe FDA approval of AbbVie's (ABBV) Skyrizi for moderately to severely active Crohn's disease was...
AbbVie raises 2027 sales forecast for new immunology drugs to $27 billion
Reuters via Yahoo Finance· 3 months ago(Reuters) -AbbVie on Friday raised its 2027 forecast for sales of its immunology drugs Skyrizi and...
2 Ultrareliable Dividend Stocks to Buy in 2024 and Hold for at Least a Decade
Motley Fool via Yahoo Finance· 4 months agoNow that 2023 is firmly in the rearview, we can say without a doubt that it was a remarkable year...
Pharma Stock Roundup: FDA Nod to Updated PFE, MRNA COVID Jabs, & More
Zacks via Yahoo Finance· 8 months agoThe FDA authorizes Pfizer (PFE) and Moderna's (MRNA) updated mRNA-based COVID-19 vaccines. Novo...
There’s a New Weight-Loss Drug Called Zepbound. Really? Zepbound?
Slate via Yahoo News· 6 months agoThis week, the world simultaneously got yet another weight-loss drug and a reason to wonder why...
AbbVie expects Botox to maintain market share as competition heats up
Reuters via Yahoo Finance· 4 months ago(Reuters) -AbbVie expects Botox's market share in the aesthetics space to remain strong even as...
2 High-Yield Healthcare Stocks to Buy With Both Hands and 1 to Avoid for Now
Motley Fool via Yahoo Finance· 3 months agoThere's one constant you can always rely on. Regardless of what's happening to the overall economy,...
Aesthetics Market Resilience: AbbVie Asserts Widely Used Botox Dominance Amidst Rising Competition
Benzinga via Yahoo Finance· 4 months agoAbbVie Inc (NYSE:ABBV) remains confident in Botox’s resilience in the aesthetics market, assured by...
Which Stock Is More Likely to Double Your Money First: Moderna or AbbVie?
Motley Fool· 2 years agoTake the case of AbbVie (NYSE: ABBV) and Moderna (NASDAQ: MRNA). AbbVie spun off from Abbott...
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, J&J and AbbVie
Zacks via Yahoo Finance· 6 months agoFor Immediate Release Chicago, IL – November 14, 2023 – Today, Zacks Equity Research discusses Eli...